BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shah NN, Sokol L. Targeting CD22 for the Treatment of B-Cell Malignancies. Immunotargets Ther 2021;10:225-36. [PMID: 34262884 DOI: 10.2147/ITT.S288546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Brzezicka KA, Paulson JC. Impact of Siglecs on autoimmune diseases. Mol Aspects Med 2023;90:101140. [PMID: 36055802 DOI: 10.1016/j.mam.2022.101140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zaib T, Cheng K, Liu T, Mei R, Liu Q, Zhou X, He L, Rashid H, Xie Q, Khan H, Xu Y, Sun P, Wu J. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy. IJMS 2023;24:2152. [DOI: 10.3390/ijms24032152] [Reference Citation Analysis]
3 Tannoury M, Garnier D, Susin SA, Bauvois B. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? Cancers (Basel) 2022;14. [PMID: 36551511 DOI: 10.3390/cancers14246026] [Reference Citation Analysis]
4 Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, Paietta E, Litzow MR, Konopleva M, Yu J, Inaba H, Ribeiro RC, Pui CH, Yang JJ. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv 2022;8:eadd6403. [PMID: 36516256 DOI: 10.1126/sciadv.add6403] [Reference Citation Analysis]
5 Prescher H, Schweizer A, Frank M, Kuhfeldt E, Ring J, Nitschke L. Targeting Human CD22/Siglec-2 with Dimeric Sialosides as Novel Oligosaccharide Mimetics. J Med Chem 2022. [PMID: 35881556 DOI: 10.1021/acs.jmedchem.2c00765] [Reference Citation Analysis]
6 Mohammadi Z, Enayati S, Zarei N, Mozhgan Zahmatkesh, Saberi S, Mafakher L, Azizi M, Khalaj V. A Novel Anti-CD22 scFv.Bim Fusion Protein Effectively Induces Apoptosis in Malignant B cells and Promotes Cytotoxicity. Appl Biochem Biotechnol 2022. [PMID: 35838885 DOI: 10.1007/s12010-022-04035-y] [Reference Citation Analysis]
7 Jiang KY, Qi LL, Kang FB, Wang L. The intriguing roles of Siglec family members in the tumor microenvironment. Biomark Res 2022;10:22. [PMID: 35418152 DOI: 10.1186/s40364-022-00369-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zhang T, Wang T, You F, Li Z, Chen D, Zhang K, Tian S, Sheng B, Wu H, Jiang L, Ma R, An G, Meng H, Yang L. Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. Transpl Immunol 2022;:101538. [PMID: 35051588 DOI: 10.1016/j.trim.2022.101538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Atallah-yunes SA, Robertson MJ. Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. Leukemia Research Reports 2022;17:100319. [DOI: 10.1016/j.lrr.2022.100319] [Reference Citation Analysis]